Related Experiment Video
Updated: Jul 4, 2025
Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection
Published on: June 5, 2021
SARS-CoV-2 Neutralization by Cell Membrane-Coated Antifouling Nanoparticles.
Hao Chen1, Xilin Xiong1, Yuan Huang1
1Collaborative Innovation Center for Advanced Organic Chemical Materials Co-constructed by the Province and Ministry, Ministry of Education Key Laboratory for the Synthesis and Application of Organic Functional Molecules, College of Chemistry and Chemical Engineering, Hubei University, Wuhan 430062, PR China.
Researchers developed novel pulmonary alveolar epithelial cell membrane-coated nanoparticles (PLGA NPs@ATII-M) to neutralize SARS-CoV-2. This low-cost COVID-19 therapeutic shows high efficiency and avoids side effects, offering a promising treatment strategy.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Infectious Diseases
Background:
- The COVID-19 pandemic necessitates effective therapeutics with minimal side effects.
- Existing treatments often cause adverse immune responses and inflammation.
- There is a critical need for low-cost, safe, and efficient COVID-19 treatments.
Purpose of the Study:
- To develop a novel nanoparticle formulation for COVID-19 treatment.
- To evaluate the efficacy of human pulmonary alveolar epithelial cell membrane-coated PLGA nanoparticles (PLGA NPs@ATII-M) against SARS-CoV-2.
- To assess the antifouling properties and targeting efficiency of the developed nanoparticles.
Main Methods:
- Preparation of solid natural human pulmonary alveolar epithelial cell (ATII) membrane-coated PLGA NPs (PLGA NPs@ATII-M).
- Utilized SARS-CoV-2 S1 protein-coated NPs (SCMMA NPs-S1) as a surrogate for coronavirus particles.
- Investigated the antifouling properties and neutralization capabilities of the PLGA NPs@ATII-M.
Main Results:
- PLGA NPs@ATII-M demonstrated remarkable affinity and competitiveness to neutralize SCMMA NPs-S1.
- The membrane-coated NPs exhibited excellent antifouling capabilities, protecting neutralization properties from protein coronas.
- The formulation showed good specificity, high targeting efficiency, and potential for avoiding side effects.
Conclusions:
- PLGA NPs@ATII-M represent a promising, low-cost candidate for COVID-19 treatment.
- The nanoparticle formulation offers effective neutralization of SARS-CoV-2 surrogates.
- The developed therapeutic approach minimizes side effects and enhances stability in circulation.
